Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Lexaria Bioscience Corp. LEXX, a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.”

Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills.

It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the award of the 24th patent, Lexaria already had a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.”

To view the full article, visit https://cnw.fm/POg2h

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Image sourced from Pixabay

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.